Sucralose
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Sucralose
- DrugBank Accession Number
- DB15049
- Background
Sucralose is an artificial sweetener used as a sugar substitute.
- Type
- Small Molecule
- Groups
- Experimental
- Structure
- Weight
- Average: 397.63
Monoisotopic: 396.0145507 - Chemical Formula
- C12H19Cl3O8
- Synonyms
- Sucralose
- Trichlorosucrose
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Adjunct therapy in maintenance of Healthy normal weight ••• ••• •••••••• •••••• - Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- International/Other Brands
- Splenda
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 96K6UQ3ZD4
- CAS number
- 56038-13-2
- InChI Key
- BAQAVOSOZGMPRM-QBMZZYIRSA-N
- InChI
- InChI=1S/C12H19Cl3O8/c13-1-4-7(17)10(20)12(3-14,22-4)23-11-9(19)8(18)6(15)5(2-16)21-11/h4-11,16-20H,1-3H2/t4-,5-,6+,7-,8+,9-,10+,11-,12+/m1/s1
- IUPAC Name
- (2R,3R,4R,5R,6R)-2-{[(2R,3S,4S,5S)-2,5-bis(chloromethyl)-3,4-dihydroxyoxolan-2-yl]oxy}-5-chloro-6-(hydroxymethyl)oxane-3,4-diol
- SMILES
- OC[C@H]1O[C@H](O[C@]2(CCl)O[C@H](CCl)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@H]1Cl
References
- General References
- Not Available
- External Links
- KEGG Compound
- C12285
- ChemSpider
- 64561
- 1439115
- ChEBI
- 32159
- ChEMBL
- CHEMBL3185084
- ZINC
- ZINC000004654665
- Wikipedia
- Sucralose
- PDB Entries
- 4rzt / 6cjv
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Treatment Eosinophilic Esophagitis 1 3 Completed Treatment Type 2 Diabetes Mellitus 1 1 Completed Not Available Human Immunodeficiency Virus (HIV) Infections 1 1 Not Yet Recruiting Treatment Clostridioides Difficile Infection / Inflammatory Bowel Diseases (IBD) 1 Not Available Recruiting Screening Alcohol Dependency 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Granule 11 mg Tablet 6.05 mg - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 12.9 mg/mL ALOGPS logP -0.39 ALOGPS logP -0.47 Chemaxon logS -1.5 ALOGPS pKa (Strongest Acidic) 11.91 Chemaxon pKa (Strongest Basic) -3 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 8 Chemaxon Hydrogen Donor Count 5 Chemaxon Polar Surface Area 128.84 Å2 Chemaxon Rotatable Bond Count 5 Chemaxon Refractivity 77.93 m3·mol-1 Chemaxon Polarizability 34.83 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-004j-0009000000-c23d82e4a948643f5f2e Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-0002-0937000000-b0228a71902cdd870ec0 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-0kdj-0609000000-ed53b58ca7e5e2c23754 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-01qa-3549000000-c97ec2c122470558cbc3 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-0f89-1932000000-77aadd7b573f03e09d1c Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-0089-9482000000-2ab67ca188b16eb46630 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 163.6097408 predictedDarkChem Lite v0.1.0 [M-H]- 163.54744 predictedDeepCCS 1.0 (2019) [M+H]+ 163.4414086 predictedDarkChem Lite v0.1.0 [M+H]+ 165.37233 predictedDeepCCS 1.0 (2019) [M+Na]+ 175.2798396 predictedDarkChem Lite v0.1.0 [M+Na]+ 171.12776 predictedDeepCCS 1.0 (2019)
Drug created at May 20, 2019 14:45 / Updated at September 03, 2020 20:54